Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

194 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Validation of an ambient measurement system (AMS) for walking speed.
Varsanik JS, Kimmel ZM, de Moor C, Gabel W, Phillips GA. Varsanik JS, et al. Among authors: de moor c. J Med Eng Technol. 2017 Jul;41(5):362-374. doi: 10.1080/03091902.2017.1308025. Epub 2017 Apr 10. J Med Eng Technol. 2017. PMID: 28394662
Impact of natalizumab on quality of life in a real-world cohort of patients with multiple sclerosis: Results from MS PATHS.
Hersh CM, Kieseier B, de Moor C, Miller DM, Campagnolo D, Williams JR, Fitzgerald KC, Xiong K, McGinley MP, Hyland M, Rudick RA, Ziemssen T, Koulinska I. Hersh CM, et al. Among authors: de moor c. Mult Scler J Exp Transl Clin. 2021 Apr 15;7(2):20552173211004634. doi: 10.1177/20552173211004634. eCollection 2021 Apr-Jun. Mult Scler J Exp Transl Clin. 2021. PMID: 33948221 Free PMC article.
Real-world effectiveness of dimethyl fumarate versus fingolimod in a cohort of patients with multiple sclerosis using standardized, quantitative outcome metrics.
Hersh CM, Altincatal A, Belviso N, Kapadia S, de Moor C, Rudick R, Williams JR, Miller C, Koulinska I. Hersh CM, et al. Among authors: de moor c. Mult Scler J Exp Transl Clin. 2022 Jan 7;8(1):20552173211069852. doi: 10.1177/20552173211069852. eCollection 2022 Jan-Mar. Mult Scler J Exp Transl Clin. 2022. PMID: 35024161 Free PMC article.
No difference in radiologic outcomes for natalizumab patients treated with extended interval dosing compared with standard interval dosing: Real-world evidence from MS PATHS.
Ryerson LZ, Naismith RT, Krupp LB, Charvet LE, Liao S, Fisher E, de Moor C, Williams JR, Campbell N. Ryerson LZ, et al. Among authors: de moor c. Mult Scler Relat Disord. 2022 Feb;58:103480. doi: 10.1016/j.msard.2021.103480. Epub 2022 Jan 2. Mult Scler Relat Disord. 2022. PMID: 35051898 Free article.
Harnessing Real-World Data to Inform Decision-Making: Multiple Sclerosis Partners Advancing Technology and Health Solutions (MS PATHS).
Mowry EM, Bermel RA, Williams JR, Benzinger TLS, de Moor C, Fisher E, Hersh CM, Hyland MH, Izbudak I, Jones SE, Kieseier BC, Kitzler HH, Krupp L, Lui YW, Montalban X, Naismith RT, Nicholas JA, Pellegrini F, Rovira A, Schulze M, Tackenberg B, Tintore M, Tivarus ME, Ziemssen T, Rudick RA. Mowry EM, et al. Among authors: de moor c. Front Neurol. 2020 Aug 7;11:632. doi: 10.3389/fneur.2020.00632. eCollection 2020. Front Neurol. 2020. PMID: 32849170 Free PMC article.
Neurofilament light levels are associated with long-term outcomes in multiple sclerosis.
Kuhle J, Plavina T, Barro C, Disanto G, Sangurdekar D, Singh CM, de Moor C, Engle B, Kieseier BC, Fisher E, Kappos L, Rudick RA, Goyal J. Kuhle J, et al. Among authors: de moor c. Mult Scler. 2020 Nov;26(13):1691-1699. doi: 10.1177/1352458519885613. Epub 2019 Nov 4. Mult Scler. 2020. PMID: 31680621 Free PMC article. Clinical Trial.
194 results